“The medical preparation of the invention produces most unexpected and beneficial results, by for example alleviating fears and anxieties which may have been present in the patient”
1/12
The patents claimed medical preparations of:
(1) ibogaine, iboga alkaloid extract, or total extract; plus
(2) amphetamine, MDA, TMA, tetrahydronapthylamine, or naphazoline
“The best results have been obtained with” MDA
The combination “forms an excellent medicine"
2/12
The ibogaine “has the effect of considerably clarifying the mind of the sick person, giving him a kind of extra-lucid vision of his ‘ego.’ It likewise excites the memory centre of the brain thus revealing memories which may go back to a period before the age of 4…”
3/12
“The amphetamine derivative associated with the iboga extract, on the other hand, permits the emotional character necessary as complement to the stimulation of the mind and imagination as produced by the iboga to be restored to the patient.”
4/12
“A toxicological study of the product has showed that secondary effects, e.g. vomiting & vertigo, are almost non-existent & that the medicine showed absolutely no danger as regards life or the biological balance of the invalid. The toxicity of this association is thus nil.”
5/12
“In view of the extreme efficiency of the medicine, it seems pointless to visualise treatments of long duration.
The medicine, when used in psychotherapy, is in fact outstanding…at no time should the practician need to exceed 5 psychotherapy sessions…”
6/12
“The spheres of application are immense.
Numerous clinical tests show that the medicine can be used in all diseases of psychosomatic character or of which the psychosomatic origin can be visualised.”
More than 50 cases were studied in psychiatry with 50 mental patients…”
7/12
Case 1:
“A woman aged 35 years was treated for symptoms corresponding to an anxiety neurosis”
5 preparatory sessions, 3 drug sessions, “one or two interviews”
“Conclusion: No re-appearance of fears and a considerable improvement in the characterological difficulties."
8/12
Case 2:
“A woman aged 23 years attended bc of conflicts w her husband. She envisaged the possibility of divorce…before taking action, she decided to find out to what point her actual refusal to her husband could be the consequence of personal psychological difficulties.”
9/12
Case 3:
“A man aged 30 years was affected by sexual troubles, homosexual tendency & sexual unsatisfaction in his conjugal life.
One treatment session which comprised a dosage of total extract of the iboga combined w MDA produced a substantial improvement to his problem.”
A primary difference between the new ‘257 & the first ‘175 patent is:
– ‘175 patent claims methods “of treating drug resistant depression” by orally administering “an oral dosage form“ of the COMP360 psilocybin Polymorph A
– ‘257 patent claims the “oral dosage form” itself
2/7
Just as with the first ‘175 patent, the new ‘257 patent claims the psilocybin Polymorph A by reference to its “XRPD diffractogram”
These are the peaks displayed when the polymorph is analyzed by X-ray
Compass unsuccessfully sought claims without these XRPD limitations
Compass is listed as collaborator on an investigator-initiated study at UC San Diego, to explore the safety, tolerability, & efficacy of psilocybin-assisted therapy for anorexia
Another study, sponsored by Imperial College London, will also assess the acceptability & efficacy of treating anorexia with psilocybin, & will use MRI & EEG to examine neuronal underpinnings of tx
Application claims compositions of “psilocybe-derived agent and a cannabis-derived agent”
”formulated in multiple layers to release the psilocybin-derived agent and the cannabis-derived agent at multiple different times, dosages and/or locations in a subject during dosing”
2/
Application asserts controlled release formulations of psilocybin + CBD can result in “multiple chemical-induced high/low shocks”
"useful in eliciting short or long term traumatic experience suppression in similar fashion to electroshock therapy without memory eradication”